Faculty: Matthieu Schapira, PhD

Matthieu Schapira, PhDMatthieu Schapira, PhD
Associate Professor

General Research Area: Computational Chemistry.

Matthieu holds a M.Sc degree in chemistry from the National Superior Chemistry School, Nancy, France, and a Ph.D in biochemistry from Ecole Normale Superieure, Paris. After graduating in 1995, he completed a couple post-docs in protein crystallography and computational chemistry at New York University Medical Center. In 2000, he joined Molsoft, a San-Diego based biotech, as senior research scientist. In 2003, he moved to Lyon, France, to lead structure-based drug design at Aptanomics/Imaxio, a drug discovery start-up. In 2007, he joined the SGC as head of research informatics. Matthieu holds an Associate Professor cross-appointment with the Department of Pharmacology and Toxicology at University of Toronto, and an adjunct Associate Professor position with the Department of Pharmacology at New York University.

SGC Toronto’s Research Informatics group has three distinct roles. (1) Research: we apply computational chemistry tools to analyze protein structures and support the development of chemical inhibitors. We also analyze cancer genomics data. (2) Tools: we develop web interfaces, such as Chromohub, to easily navigate structural, chemical and genomic data. (3) Databases: we manage the wealth of biological and chemical data generated at SGC-Toronto.

Selected Publications:

Chemical Inhibition of Protein Methyltransferases. Schapira M
Cell Chem Biol. 2016 . doi: 10.1016/j.chembiol.2016.07.014
PMID: 27569753

Discovery of a Potent and Selective Coactivator Associated Arginine Methyltransferase 1 (CARM1) Inhibitor by Virtual Screening.Ferreira de Freitas R, Eram MS, Smil D, Szewczyk MM, Kennedy S, Brown PJ, Santhakumar V, Barsyte-Lovejoy D, Arrowsmith CH, Vedadi M, Schapira M
J. Med. Chem.. 2016 . doi: 10.1021/acs.jmedchem.6b00668
PMID: 27390919

Discovery of a Potent Class I Protein Arginine Methyltransferase Fragment Inhibitor. Ferreira de Freitas R, Eram MS, Szewczyk MM, Steuber H, Smil D, Wu H, Li F, Senisterra G, Dong A, Brown PJ, Hitchcock M, Moosmayer D, Stegmann CM, Egner U, Arrowsmith C, Barsyte-Lovejoy D, Vedadi M, Schapira M - J. Med. Chem.. 2016 . doi: 10.1021/acs.jmedchem.5b01772
PMID: 26824386

Probing the epigenome. Huston A, Arrowsmith CH, Knapp S, Schapira M
Nat. Chem. Biol.. 2015 11(8):542-5. doi: 10.1038/nchembio.1871
PMID: 26196765

Discovery of a Dual PRMT5-PRMT7 Inhibitor.Smil D, Eram MS, Li F, Kennedy S, Szewczyk MM, Brown PJ, Barsyte-Lovejoy D, Arrowsmith CH, Vedadi M, Schapira M
ACS Med Chem Lett. 2015 6(4):408-12. doi: 10.1021/ml500467h
PMID: 25893041

A global assessment of cancer genomic alterations in epigenetic mechanisms.Shah MA, Denton EL, Arrowsmith CH, Lupien M, Schapira M
Epigenetics Chromatin. 2014 7(1):29. doi: 10.1186/1756-8935-7-29
PMID: 25484917

Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors.Yu W, Chory EJ, Wernimont AK, Tempel W, Scopton A, Federation A, Marineau JJ, Qi J, Barsyte-Lovejoy D, Yi J, Marcellus R, Iacob RE, Engen JR, Griffin C, Aman A, Wienholds E, Li F, Pineda J, Estiu G, Shatseva T, Hajian T, Al-Awar R, Dick JE, Vedadi M, Brown PJ, Arrowsmith CH, Bradner JE, Schapira M
Nat Commun. 2012 3:1288. doi: 10.1038/ncomms2304
PMID: 23250418

Epigenetic protein families: a new frontier for drug discoveryArrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M
Nat Rev Drug Discov. 2012 11(5):384-400. doi: 10.1038/nrd3674
PMID: 22498752

Druggability of methyl-lysine binding sitesSantiago C,Nguyen K,Schapira M
J Comput Aided Mol Des.. 2011 25 (12):1171-8. doi: 10.1007/s10822-011-9505-2
PMID: 22146969


Structural Genomics Consortium
101 College St. , South Tower, Rm 713
Toronto, Ontario
M5G 1L6
Phone: 416-978-3092
Email: matthieu.schapira@utoronto.ca

Back to Top